Orforglipron (Foundayo): the first GLP-1 pill with no restrictions, and why it isn't available in Spain

Orforglipron is one of the stories of 2026 in obesity treatment, and for one very specific reason: it is a pill. Not a weekly injection — a daily tablet you can take at any time of day, with or without food.

Orforglipron is not authorised in Spain

The FDA approved it on 1 April 2026 under the brand name Foundayo, but that is the United States. In the European Union it is not approved, it does not appear in the AEMPS register, and we have not even been able to publicly confirm that an application has been submitted to the EMA. The fact that Lilly has a Spanish-language product website means nothing: it is aimed at the Spanish-speaking market in the United States.

This is not a technicality: it means no Spanish prescription can be written for it and no Spanish pharmacy can dispense it. If a website offers it to you, it is not selling you a medicine with any guarantees — whatever turns up at your door, nobody has verified what is in it.

What makes it different

It is a non-peptide GLP-1 receptor agonist: a small molecule, not a protein. That chemical difference is the whole story, because proteins are broken down in the stomach, which is why semaglutide and tirzepatide have to be injected.

A pill already existed. The difference is in how you take it

Rybelsus (oral semaglutide) has been on the market for years, but its absorption is so fragile that it demands a ritual: on an empty stomach first thing in the morning, with no more than 120 ml of plain water, and waiting 30 minutes before eating, drinking or taking any other tablet.

Orforglipron, according to the manufacturer, can be taken at any time of day, with no food or water restrictions. That is literally the headline of the approval, and it is a real difference: it does not change what the drug does, it changes whether someone can stick with it for years.

What the FDA approved it for (and what it did not)

For adults with obesity, or with overweight accompanied by weight-related medical problems. It is NOT approved for type 2 diabetes — there are Spanish-language sources claiming otherwise and that is false. The diabetes studies do exist, but that indication is not authorised.

What its trials found

ATTAIN-1 — obesity

3,127 participants, 72 weeks, doses of 6, 12 and 36 mg versus placebo. Published in the New England Journal of Medicine in September 2025. Mean weight loss:

• 6 mg — −7.8%
• 12 mg — −9.3%
• 36 mg — −12.4%

Of those taking 36 mg, 59.6% lost at least 10% of their body weight. We are not giving the placebo group figure here because the manufacturer's public sources offer two different values depending on how it is counted, and we are not going to publish a number we cannot reconcile.

ACHIEVE-1 — type 2 diabetes

559 participants, 40 weeks. Published in the NEJM in June 2025. Glycated haemoglobin fell by 1.48 points on the 36 mg dose, versus 0.41 with placebo, and by the end of the trial the average was between 6.5% and 6.7% with orforglipron. Weight loss was 7.6% — considerably less than in ATTAIN-1, which is what you would expect: in people with type 2 diabetes these drugs usually produce considerably less weight loss than in people without it.

The side effects

They are the ones typical of the class, and they are no milder for coming in tablet form. In ATTAIN-1, on the 36 mg dose versus placebo:

• Nausea — 33.7% versus 10.4%
• Constipation — 25.4% versus 9.3%
• Diarrhoea — 23.1% versus 9.6%
• Vomiting — 24.0% versus 3.5%
• Discontinuation due to adverse effects — 10.3% versus 2.7%

The FDA prescribing information also lists headache, dyspepsia, abdominal pain, bloating, fatigue, belching, heartburn, flatulence and hair loss.

How it compares with what already exists (and why the comparison is misleading)

This is the table everyone publishes. We are publishing it too, with the warning almost nobody includes: these figures are NOT comparable with one another.

• Semaglutide 2.4 mg (Wegovy) — STEP-1: −14.9% at 68 weeks, versus −2.4% with placebo. Published in the NEJM (2021).
• Tirzepatide 15 mg (Mounjaro/Zepbound) — SURMOUNT-1: −20.9% at 72 weeks, versus −3.1% with placebo. Published in the NEJM (2022).
• Orforglipron 36 mg (Foundayo) — ATTAIN-1: −12.4% at 72 weeks. Published in the NEJM (2025).
• Retatrutide 12 mg — TRIUMPH-1: −28.3% at 80 weeks. Lilly press release and presentation at ADA 2026. Not published in a peer-reviewed journal.
• CagriSema 2.4/2.4 mg — REDEFINE-1: −22.7% at 68 weeks, versus −2.3% with placebo. Published in the NEJM (2025).

Why you cannot read that list as a league table

• The trials run for different lengths of time. From 68 to 84 weeks. Weight loss curves have not plateaued by 68 weeks, so giving a drug 12 extra weeks hands it an advantage without it having done anything better.
• The populations are different. Starting weight, age, sex and comorbidities do not match. It is well established that the same molecule produces considerably less weight loss in people with type 2 diabetes than in people without it: mixing populations invalidates any ranking.
• The placebos do not match either. The placebo group lost −2.4% in STEP-1, −3.1% in SURMOUNT-1 and −2.2% in TRIUMPH-1. A different placebo means a different lifestyle intervention behind it — in other words, a different starting line.
• Not all the figures are peer-reviewed. Four come from the New England Journal of Medicine. The retatrutide figure comes from a company press release. They are not the same class of evidence.

The only thing that does prove something: the two head-to-head trials

Only twice have two of these drugs been pitted against each other in the same trial, with the same people, at the same time. These are the only data on this page that allow anyone to say one is better than another.

• SURMOUNT-5 — tirzepatide 15 mg versus semaglutide 2.4 mg, 72 weeks: −20.2% versus −13.7%. Tirzepatide won.
• REDEFINE-4 — CagriSema versus tirzepatide 15 mg, 84 weeks: −23.0% versus −25.5%. It did not meet its non-inferiority endpoint. In other words: CagriSema failed even to show it was equivalent.

Look at the contrast. In the list above, CagriSema (−22.7%) appears to beat tirzepatide (−20.9%). When they were actually measured against each other, head to head, tirzepatide won. That is exactly what it means to say figures from different trials are not comparable — and why that list is not a league table.

Orforglipron and retatrutide have never been measured against anything other than placebo. When someone tells you that either of them "is better" than what already exists, there is no trial behind that sentence.

And note what that list implies for orforglipron: it produces the least weight loss of the four. Its advantage is not potency — it is that you take it with no ritual and no needles. Which of those two things matters more is not a question with a one-size-fits-all answer.

What is available in Spain today

Orforglipron is not available in Spain and nobody can tell you today when it will be: the dates circulating online do not come from the manufacturer or from any regulator. That is the point to take away from this guide.

The need that makes it so eagerly awaited, on the other hand, does already have a legal answer. Medical weight-loss treatment is available in Spain today, with a prior assessment, a prescription where appropriate from a registered doctor, and ongoing follow-up from the medical team. You can check whether you are eligible.

And to keep getting to grips with the subject: what GLP-1 drugs are and how they work, how Mounjaro and Ozempic differ and the only legal way to access them.